Background {#Sec1}
==========

Thyroid cancer (TC) is one of the most frequent endocrine malignancies, accounting for 3--4% of cancers \[[@CR1]\], and its occurrence has increased by approximately 5% on a yearly basis, with higher prevalence in females than in males (20.6 vs. 6.9 new cases per 1000 persons) \[[@CR2]\]. The number of newly diagnosed cases has risen dramatically in the last 10 years, which could be partially ascribed to the availability of more sensitive diagnostic tools, i.e., ultrasonography and fine-needle aspiration (FNA) and the smaller size of diagnosed tumors. However, over diagnosis is also an issue because its occurrence rate has risen 15-fold since 2003, whereas mortality rates have not changed \[[@CR3]\].

In general, the 5- and 10-year survival rates for TC patients are excellent (approx. 98%) but are related to the age of the patient at the time of diagnosis and the cancer subtype \[[@CR1], [@CR4], [@CR5]\].

Both papillary (PTC) and follicular thyroid carcinoma (FTC) arise from follicular epithelial thyroid cells involved in iodine metabolism. PTC and FTC, together with the less common Hürtle cell carcinoma, are classified as differentiated thyroid cancer (DTC, see Fig. [1](#Fig1){ref-type="fig"}) \[[@CR6], [@CR7]\]. Both PTC and FTC progress slowly and are generally characterized by good prognosis, especially if diagnosed early \[[@CR5]\].Fig. 1Overview of thyroid cancer types and their origins

Undifferentiated anaplastic thyroid carcinoma (ATC) is the most aggressive TC type. Although ATC also originates from follicular cells, similar to PTC and FTC, it does not possess their original biological properties \[[@CR8]\]. ATC represents 2--5% of cases, (77% in women) with the worst prognosis and a 5-year survival rate of 5% \[[@CR3]\]. ATC is insensitive to conventional methods of treatment \[[@CR9]\].

In contrast, medullary thyroid cancer (MTC) is derived from parafollicular thyroid "C" cells, which produce calcitonin \[[@CR2]\].

The majority of TC cases are sporadic, with only 5% of DTC characterized as familial (mostly PTC) and \~ 25% of MTC inherited as an autosomal trait \[[@CR10]\]. Only sporadic tumors are analyzed in this review.

Although most mutations found in TC differ among types, certain DNA alterations were found to be common in more than one subtype. As discussed later in this review, ATC tumors appear to derive from other differentiated tumors and thus possess a large overlap with mutations present in DTCs, such as *TMPRSS4*. Mutations in certain genes, e.g., *CHEK2,* are reported in both PTC and FTC, although not with the same prevalence \[[@CR11], [@CR12]\], and their potential contribution to TC carcinogenesis is described in the respective paragraphs. In this work, we focus on tumor heterogeneity and the mutation burden carried by thyroid tumors, as tested primarily by high-throughput methods performed within larger genomic projects, including The Cancer Genome Atlas (TCGA).

We gathered the data from RNA expression and DNA sequencing experiments and identified potential genetic biomarkers of disease progression. Genome-wide association studies (GWAS) as well as sequencing and microarrays were considered. In this work, we present an overview of the available biomarkers candidates for progression and development of thyroid cancer and drivers of carcinogenesis, as discussed in detail in the respective sections. All gene functions were inferred using GeneCards ([www.genecards.org](http://www.genecards.org)) \[[@CR13]\].

Genome-wide studies significantly aid in the identification of cancer-specific germline and somatic mutations, which can contribute to more sensitive diversification of cancer subtypes and facilitate early diagnosis. Identification of disease-specific point mutations can accelerate the evaluation of candidate target genes for therapeutic drugs and the search for novel driver mutations. However, the identification of polymorphisms (SNPs) could additionally improve prognosis and patient outcomes.

Common genetic determinants of thyroid cancer subtypes {#Sec2}
------------------------------------------------------

In recent years, the development of sequencing and microarray technologies has permitted a whole-genome search for TC-linked or associated genes. Genome-wide association studies (GWAS) are a highly potent method for identification of high-incidence single nucleotide polymorphisms (SNPs) and copy number variations (CNVs). Recently, GWAS were used to study large TC patient cohorts \[[@CR14]--[@CR17]\] and were followed by studies confirming the findings \[[@CR18]--[@CR27]\]. Mutation hot spots identified through GWAS (microarray, next-generation sequencing (NGS) and high-resolution melting (HRM)) are collected in Table [1](#Tab1){ref-type="table"}. Specific SNPs could be associated with susceptibility to DTC (mostly papillary and follicular) in single or multiple populations with variable strength.Table 1Somatic mutations associated with susceptibility to differentiated thyroid cancersChromosomal locationDbSNP identification No.GeneGene functionCancer typeTested populationLiterature1p31.3rs334725*NFIA*Nuclear transcription factorPTC, FTCIcelandic, American, Dutch, SpanishGudmundsson et al.*,* 20121q42.2rs12129938*PCNXL2*Correlated with tumorigenesis of colorectal carcinomasDTCIcelandic, American, Spanish, DutchGudmundsson et al.*,* 20172q35rs966423, rs6759952*DIRC3*lincRNAPTC, FTCIcelandic, American, Dutch, Spanish, PolishGudmundsson et al.*,* 2012, Liyanarachchi et al.*,* 2013DTCItalian, Polish, Spanish, EnglishKöhler et al.*,* 20133q25.32rs7617304*RARRES1*Membrane protein gene responsive to retinoid acidDTCItalianKöhler et al.*,* 20133q26.2rs6793295*LRCC34* near *TERC* (missense)RNA telomerasePTC, FTCIcelandic, American, Spanish, DutchGudmundsson et al.*,* 20174q34.3rs17739370 TT variant*NEIL3*DNA repair, BERDTCItalianCipollini et al.*,* 20165q22.1rs73227498*NREP* and *EPB41L4A*Intergenic regionPTC, FTCIcelandic, American, Spanish, DutchGudmundsson et al.*,* 20175rs13184587*ARSB* intronIntron of lysosomal sulfataseDTCItalianFiglioli et al.*,* 20147q21rs10238549, rs7800391*IMMP2L*Processing of signal peptides in mitochondrial membraneDTCItalianKöhler et al.*,* 20138p12rs2439302*NRG1*membrane glycoprotein, signaling mediatorPTC, FTCIcelandic, American, Dutch, SpanishGudmundsson et al.*,* 20128q24rs6983267ncRNAN/APTCEnglishJones et al.*,* 20129q3.3rs10781500*SNAPC4*Large subunit of the DNAP complexDTCItalianKöhler et al.*,* 20139q22.33rs965513, rs1867277 (5'UTR region), rs71369530Proximity to *FOXE1*Deregulation of thyroid morphogenesisPTCIcelandic, Caucasian, Asian, Cuban, English, Belarussian, French PolynesianJones et al.*,* 2012, Gudmundsson et al.*,* 2009, Liyanarachchi et al.*,* 2013, Damiola et al.*,* 2014, Wang et al.*,* 2016, Pereda et al.*,* 2015, Maillard et al.*,* 201510q24.33rs7902587near *OBFC1*Stimulator of DNA replication initiation factorPTC, FTCIcelandic, American, Spanish, DutchGudmundsson et al.*,* 201711rs1801516*ATM*Cell-cycle checkpoint, response to DNA damageDTCCuban women after multiple pregnancies, French PolynesianPereda et al.*,* 2015, Maillard et al.*,* 201513rs1220597*SPATA13* intronRegulation of cell migration and adhesion, guanine nucleotide exchange factorDTCItalianFiglioli et al.*,* 201414q13.3rs116909374*NKX2--1*Thyroid-specific transcription factorPTC, FTCIcelandic, American, Dutch, Spanish, PolishGudmundsson et al.*,* 2012, Liyanarachchi et al.*,* 201314q13.3rs944289Close to *NKX2--1*Thyroid-specific transcription factorPTC, FTCIcelandic, Cuban, English, American, Polish, French PolynesianJones et al.*,* 2012, Gudmundsson et al.*,* 2009, Liyanarachchi et al.*,* 2013, Pereda et al.*,* 2015, Maillard et al.*,* 201514241(Thr \> Met)*XRCC3*DNA repair, homologous recombinationDTCChinese, Iranian, Caucasian PortugueseWang et al.*,* 2015, Fayaz et al.*,* 2014, Bastos et al.*,* 200914rs10136427*BATF*Transcription factor, negative regulator of AP-1/ATF transcriptional eventsDTCItalian, Polish, SpanishFiglioli et al.*,* 201415q22.33rs2289261, rs56062135*SMAD3*Transcriptional modulatorPTC, FTCIcelandic, American, Spanish, DutchGudmundsson et al.*,* 201720rs7267944*DHX35*RNA helicasesDTCItalian, Polish, SpanishFiglioli et al.*,* 2014Variants determined by GWAS. *DTC* Unspecified differentiated thyroid cancer, *PTC* Papillary thyroid cancer, *FTC* Follicular thyroid cancer

Sixteen case/control studies allowed identification of 27 SNPs located primarily within the coding regions (see Table [1](#Tab1){ref-type="table"}). Only rs6983267 was located in the non-coding RNA; rs1220597, rs73227498, and rs13184587 were located in the introns; and rs965513, rs1867277, rs71369530 and rs944289 were located in proximity to *NKX2--1*. This observation might stem from the fact that most microarray and NGS experiments are focused on transcriptome analysis and can be biased against regulatory or non-coding fragments. TC-associated genes are often connected to DNA-damage repair or transcription.

Using a slightly different approach, Gudmundsson et al.*,* selected 22 SNPs based on a score of high association with high levels of thyroid stimulating hormone in a GWAS study of over 27,000 samples from an Icelandic population \[[@CR16]\]. The results of genotyping of 561 samples of the non-medullary type were compared with over 40,000 controls from different populations (Dutch, American and Spanish). Three variants proved to be significantly correlated, namely, rs966423 in non-coding RNA-*DIRC3* (OR = 1.34, *P* = 1.3·10^− 9^), rs2439302 membrane glycoprotein involved in cell signaling *NRG1* (OR = 1.36, *P* = 2.0·10^− 9^) and rs116909374 in thyroid-specific transcription factor *NKX2--1* (OR = 2.09, *P* = 4.6·10^− 11^), and their functions in thyroid tumorigenesis are still unknown.

The ThyroSeq microarray panel (ThyroSeq) is widely used and offers the possibility of testing more than 1000 hotspots in 14 TC-related genes and over 40 fusions simultaneously. Nikiforova and Nikiforov tested over 800 TC samples of all types using ThyroSeq panels, thus proving its usefulness in detection and classification of cancerous tissue \[[@CR28]--[@CR30]\].

Figlioli et al.*,* performed SNP genotyping of an Italian population (case/controls: 1437/1534), validated in DTC patients from Poland (case/controls: 448/424) and Spain (case/controls: 375/408) \[[@CR14]\]. The strongest correlation among all tested cohorts was found for rs10136427 localized in transcription regulator *BATF*, (OR = 1.40, *P* = 4.35·10^− 7^) and rs7267944 in putative RNA helicase *DHX3* (OR = 1.39, *P* = 2.13·10^− 8^).

Gudmundsson et al.*,* published a follow-up study in Icelandic, Dutch, Spanish and 2 American populations (case/controls: 1003/278,991, 85/4956, 83/1612, 1580/1628 and 250/363, respectively) confirming 5 novel loci associated with non-medullary thyroid cancer (P~combined~ \< 3 × 10^− 8^), i.e., rs12129938, rs6793295, rs73227498, and two independently associated variants, i.e., rs2289261 (OR = 1.23; *P* = 3.1·10^--9)^ and rs56062135 (OR = 1.24; *P* = 4.9·10^− 9^) \[[@CR31]\].

Applying a presumption that the DNA repair genes of base (BER) or nucleotide (NER) excision repair pathways might be involved in TC tumorigenesis, Cipollini et al.*,* genotyped known SNPs in 450 case-control paired DTC samples from an Italian population \[[@CR32]\]. The TT variant of base excision repair gene *NEIL3*, which codes a DNA glycosylase, was associated with increased risk of DTC. Another GWAS study on an Italian population performed by Köhler et al. associated mutations in non-coding RNA genes *DIRC3*, *RARRES1*, *SNAPC4* and *IMMP2L* with increased DTC in a high-incidence population of 690 cases and 497 controls and confirmed this finding in 3 low-incidence populations (total of 2958 cases and 3727 controls) \[[@CR15]\] (See Table [1](#Tab1){ref-type="table"}). *SNAPC4* encodes a large subunit of the RNA-activation protein complex, and *RARRES1* and *IMMP2L* are transmembrane proteins.

Papillary thyroid Cancer (PTC) {#Sec3}
------------------------------

Derived from follicular cells, papillary thyroid cancer is named after its cyto-architecture and can be further divided into 3 subtypes based on histotype: tall cell variant (TCV), follicular, and classical (most common) \[[@CR33]\]. According to TCGA, up to 70% of somatic PTC drivers are found in activators of the MAPK pathway and include *BRAF*, *RAS* and rearrangements of the *RET* and *NTRK1* genes \[[@CR5]\] (See Table [2](#Tab2){ref-type="table"}). The alterations are generally thought to be mutually exclusive in PTC \[[@CR34]--[@CR37]\], but contradictory data have emerged \[[@CR38]--[@CR41]\]. Other mutations such as *PTEN* and *PIK3CA* \[[@CR42]\] have been reported at lower frequencies (2/86 (2.32%) and 3/86 (3.48%), respectively). The mutation density is relatively low at 0.41 mutations/Mb for PTC and 0.5 mutations/Mb for TCV. PTC is often multifocal, with a main tumor (\> 1 cmØ) and several microcarcinomas \[[@CR43], [@CR44]\]. Nodules might be positioned unilaterally or bilaterally in the thyroid lobes. Multifocality is a characteristic of up to 40% of all PTC, \[[@CR45], [@CR46]\] leading to aggressiveness and resistance to radioiodine treatment \[[@CR47]\]. The clonal origin of each singular carcinoma is not necessarily the same because tumors might arise independently through a series of molecular events, such as chromosome X inactivation \[[@CR43], [@CR48]--[@CR52]\], but certain authors suggest clonal homogeneity between the nodules \[[@CR49], [@CR53]--[@CR57]\].Table 2Somatic mutations characteristic of PTCsGeneLocalizationGene functionMutationDefect in cancerClinical correlationLiteratureGene*BRAF*7q34Serine/threonine kinase, response to cell growth factorsB-type Raf Kinase (chr 7) 2 Missense mutation V600E (T \< A 1799), rs113488022Constitutive activation of MAPK pathwayPositive correlation with age, marker of TCV subtypeTCGA, Kimbrell et al.*,* 2015, Lu et al.*,* 2016, Gandolfi et al.*,* 2013, Kim et al.*,* 2006, Guerra et al.*,* 2012, Sun et al.*,* 2016, Gertz et al.*,* 2016, Iyer et al.*,* 2015, Lee et al.*,* 2016*CHEK2*22q12.1Cell cycle checkpoint kinaseIVS2 + 1G \> A, 1100delC or del5395, missense mutation I157TDNA repair mechanism dysfunctionsPositive correlation with cancer aggressivenessSiolek et al.*,* 2015, Wójcicka et al.*,* 2014, Kaczmarek-Ryś et al.*,* 2015*DLL4*15q15.1Notch signaling mediatorPatient specific mutationsPromotes angiogenesisCorrelated with presence of lymph node metastasesLe Pennec et al.*,* 2015*EIF1AX*Xp22.12Translation initiation factor, transfer of Met-tRNAfHotspot at A113_splice site intron 5/exon 6Potential driver mutationN/ATCGA, Forbes 2011, Martin 2013, Karanamurthy 2016*FOXE1*9q22.33Transcription factorrs965513 AA, AG; rs944289; c.821C \> A, p.P54Q; c.943A \> C p.K95Q; c.994C \> T, p.L112FDeregulation of thyroid morphogenesisThyroid cancer susceptibility markerMond et al.*,* 2015, Gudmundsson et al.*,* 2009, Penna-Martinez et al.*,* 2014*PIK3CA*3q26.32PI3K/AKT/mTOR pathway effectorE545AMutation of helical domainN/ALee et al.*,* 2016*PTEN*10q23.31PI3K/AKT/mTOR pathway effectorN/AProduces a truncated proteinN/AXing et al.*,* 2013*RAS*11p15.5, 1p13.2, 12p12.1Signal transductionH-Ras (chr11), N-Ras (chr1), K-Ras (chr12)Preferential activation of PI3K-AKT pathwayPositive correlation with cancer aggressivenessRossi et al.*,* 2015, Gertz et al.*,* 2016, Abubaker et al.*,* 2008, Zou et al.*,* 2014*TERT* promoter5p15.33Telomerase reverse transcriptaseC \> T 1295228 and 1,295,250 C \> A at 1295250Gain of immortalityPositive correlation with cancer aggressivenessBae et al.*,* 2016, Liu et al.*,* 2014, Liu et al.*,* 2013, Sun et al.*,* 2016Chromosomal Abberations*RET*10q11.21Tyrosine kinase transmembrane receptorRearrangements: RET/PTC1, RET/PTC2, RET/PTC3, RET/PTC4. RET/PTC5, RET/PTC6, RET/PTC7, RET/PTC8, RET/PTC9, PCM1-RET, EKLS-RET, FKBP-RET, RET-ANK3, TBL1XR1-RET, AKAP13-RET, ERC1-RET, HOOK3-RET, SPECC1L-RET, ACBD5-RET, ΔRFP-RETDownstream signaling of MAPK and PI3K pathways, evasion of apoptosisCommon in pediatric PTC, common co-occurrence with BRAF mutationTCGA, Gertz et al.*, 2*016, Rossi et al.*,* 2015, Hamatani et al.*,* 2014, Corvi et al.*,* 2000, Ciampi et al.*,* 2007, Klugbauer et al.*,* 1998, Salassidis et al.*,* 2000, Saenko et al.*,* 2003, Nakata et al.*,* 1999, Hamatani et al.*,* 2014, Bongarzone et al.*,* 1993, Grieco et al.*,* 1990Abnormal expression*ATP5E*20q13.32ATPase subunit 5EDown-regulationDisruption of ATP synthesis in mitochondriaPotential PTC biomarkerHurtado-Lopez et al.*,* 2015*MUC1*1q22Proliferation and signaling of epithelial cellsOverexpressionLeads to propagation of tumorigenesis and metastasisPoor outcome markerRenaud et al.*,* 2014*TMPRSS4*11q23.3Serine proteaseOverexpressionMigration and metastasis of cancer cellsMalignant tumorsKebebew et al.*,* 2005, Jarzab et al.*,* 2005, Guan et al.*,* 2015*YY1*14q32.2Transcription factorOverexpressionLeads to increased cell proliferationPositive correlation with ageArribas et al.*,* 2015Regulation Of Expressionmicro RNAXp11.3Regulation of expression of affiliated geneslet-7 miRNA overexpressionDisruption of regulatory pathways (e.g. DNA damage response, stress response), propagation of cancer growth and expansion through down/up-regulation of target genesN/ASalajegheh et al.*,* 2016, Yoruker et al.*,* 2016, Lee et al.*,* 2013, Zhang et al.*,* 2010, Lei et al.*,* 2016, Hong et al.*,* 2016, Samsonov et al.*,* 2016, Hu et al.*,* 20179p21.3miR-31 overexpression8q24.3miR-146b overexpression19q13.41miR-151-5p overexpression10q24.32miR-221 overexpressionXp11.3miR-222 overexpression17q23.1miR-21 down-regulation9q34.3miR-126 down-regulation19p13.12miR-20bXq26.2miR-639

Genetic alterations in kinases {#Sec4}
------------------------------

### BRAF {#Sec5}

The most common somatic mutation occurring in PTC is a mis-sense *BRAF* mutation resulting in thymine-to-adenine substitution at position 1799 of the B-type Raf Kinase (*BRAF*) gene. This mutation leads to a valine-to-glutamate substitution at codon 600 of the BRAF protein (BRAF^V600E^) and constitutive activation of the MAPK signaling pathway via activation of the G-coupled receptor in the membrane \[[@CR58]--[@CR60]\], and it is common for several cancers, including non-small cell lung cancer and melanomas. \[[@CR59]--[@CR61]\]. BRAF is an activator of BRAF-activated non-coding RNA (*BANCR*), which regulates many cellular processes, including tumorigenesis, metastasis and, apoptosis \[[@CR62]\]. BRAF can function as both a tumor suppressor and disease progression factor \[[@CR63]\]. BRAF^V600E^ is typical for TCV and classical subtypes, whereas *RAS* mutations predominantly drive the follicular subtype \[[@CR33], [@CR64]\]. This dependence, in combination with the various prevalence of driver mutations in populations, might explain certain of the disparities between different studies.

Recently, the potential heterogeneity of *BRAF* mutants (intra- and inter-tumoral) has been emphasized using both traditional methods (PCR verified by Sanger sequencing) as well as novel techniques such as exome capture and pyrosequencing. Kimbrell et al.*,* tested 57 tumors from 27 patients for the presence of the *BRAF* ^*V600E*^ mutation \[[@CR65]\]. The results were discordant between primary and secondary tumors in 10 out of 27 cases, but no significant histological changes were observed. However, the irregularity of the tumor edge appears to indicate its metastatic origin. No correlation was detected for the lobe positioning of the concordant and discordant nor the size of *BRAF*-positive and negative tumors. Sun et al.*,* showed (*n* = 455) that 75.5% of the patients in a Chinese population harbored a *BRAF*^*V600E*^ mutation, which was significantly correlated with increasing patient age \[[@CR66]\]. In contrast, the rate of *BRAF*^*V600E*^ mutations was two times lower in children than in adults \[[@CR67]\]. One of 14 pediatric patient samples was positive for concomitant *BRAF* mutation and *RET/PTC3* rearrangement (see below). Lu et al.*,* identified *BRAF*^*V600E*^ mutation as the most common using deep sequencing of 21 foci from 8 patients \[[@CR68]\]. The experiments confirmed that multifocal TC could be heterogeneous and that *BRAF* is not necessarily the driver because up to 75% of the clones had independent clonal origins. Those results were supported by reports from other groups in which foci did not share the same mutation patterns \[[@CR48], [@CR69]--[@CR71]\]. Gandolfi et al.*,* tested 37 primary PTC tumors and 95 metastases in adults and found that 43.9% of the samples were *BRAF*-positive, but no correlation was observed with metastasis. The allele percentage shows that *BRAF* mutations are heterogeneous and rarely a result of a clonal event \[[@CR69], [@CR72]\]. De Biase et al.*,* tested the distribution of neoplastic cells in *BRAF*^*V600E*^-positive tumors (*n* = 85/155) \[[@CR51]\]. The percentage of cells harboring a mutated *BRAF* allele present in each sample varied from less than 30% (*n* = 9/85) to 80% (*n* = 39/85). Down-regulation of the transcript was observed in paired PTC tumor samples and normal adjacent tissues. Real-time PCR shows that the down-regulation of *BANCR* correlates with patient prognosis with consideration of tumor size, number of nodules, stage, gender, metastasis and extrathyroidal extensions but not with age.

### PIK3CA {#Sec6}

Mutations in *PIK3CA*, a catalytic subunit of the phosphatidylinositol 3-kinase and a component of the PI3K/Akt signaling pathway, were found by Lee et al. in a targeted sequencing experiment (*n* = 240). One sample carried a *PIK3CA*^*E542K*^ mutation (0.4%), 24 p.E545A mutation (10%) and 138 concomitant *BRAF*^*V600E*^ and *PIK3CA*^*E454A*^ mutations (57.7%) \[[@CR73]\]. Independently, Wang et al.*,* found 20 samples carrying the *PIK3CA* copy gain mutation (14%, *n* = 141) \[[@CR74]\].

### *RET* proto-oncogene {#Sec7}

The *RET* proto-oncogene encodes a tyrosine kinase receptor \[[@CR75], [@CR76]\], and *RET* activation promotes downstream signaling, leading to cell proliferation, differentiation and survival. \[[@CR75]\]. Depending on the length of the C-terminus of the RET protein, three splice variants of the *RET* mRNA can be distinguished, namely, *RET9*, *RET43* and *RET51*, and all present different cellular localization and function \[[@CR77]\]. In PTC, gene fusions are the most common, but *RET* gene mutations were also associated with tumorigenesis, specifically *RET* G691S (rs1799939), L769 L (rs1800861) and S904S (rs1800863) \[[@CR78]\]. Khan et al.*,* suggested that rare variants G691SA and S904S are more prevalent in PTC and might be associated with a predisposition to TC development, as opposed to the underrepresented L769 L variant. However, this study was conducted on blood samples of post-thyroidectomy patients, thus the sensitivity of the assay remains to be determined.

Gene fusions {#Sec8}
------------

### *RET/PTC* gene fusions {#Sec9}

The variants of *RET* rearrangements are characterized by the fusion of the kinase domain to the 5′ terminus of the donor gene, resulting in a change of the subcellular localization of the receptor to the cytosol and leading to constitutive activation of the MAPK signaling pathway \[[@CR79]\]. Until now, 25 fusion variants were described, 19 of which are associated with PTC \[[@CR33], [@CR80]--[@CR92]\]. The *RET* kinase domain and 5′ end of *CCD6* gene (*RET/PTC1*) fusion \[[@CR84]\] or the nuclear receptor co-activator 4 gene (*NCOA4*) (*RET/PTC3*) are most common \[[@CR81]\]. Zou et al.*,* reported a 14% rate of *RET/PTC* rearrangement and co-occurrence of *BRAF*^*V600E*^ with *RAS/PTC1* (*n* = 82) \[[@CR93]\]. Rossi et al., tested fine-needle aspiration of PTC samples by real-time PCR and showed that in 7.3% of the 940 samples, either *RET/PTC1* or *RET/PTC3* was present \[[@CR37]\]. Six of the patients had both *RET* rearrangement and *BRAF* mutation. *RET* rearrangement appears to be fairly common in children with PTC \[[@CR67]\]. Out of 13 samples in the study, *RET* gene fusions were detected in 2 (15%) samples by fluorescence in situ hybridization (FISH) assay.

### KAZN--C1ORF196 {#Sec10}

Le Pennec et al.*,* identified 4 novel gene fusions, most prominently *KAZN--C1ORF19*6 \[[@CR94]\], and this finding was confirmed in both a case study and in 85% of additional PTC samples (*n* = 94). *KAZN* encodes a keratinization-associated adhesion protein, whereas *C1ORF19*6 is a putative gene. The biological function of such gene fusion is unknown, but it is predicted to be a result of an alternative splicing event generates a transcript coding for an in-frame protein. RNA sequencing of 115 samples from thyroid tumor tissues and metastases was performed, and 87 samples classified as PTC were sequenced using the Sanger method to validate the existing mutations \[[@CR94]\]. *KAZN--C1ORF19*6 gene fusion was absent in both tumor-adjacent (*n* = 37) and normal thyroid tissue (*n* = 23). Other mutations specific for the patients were identified, all of which highlight the tumor genetic heterogeneity. What is remarkable about this study is the fact that most of the mutations found were specific for a particular patient only.

Mutations of DNA-repair genes {#Sec11}
-----------------------------

### CHEK2 {#Sec12}

Mutations in DNA repair genes appear to be mutually exclusive with MAPK activator mutations such as *BRAF*^*V600E*^, but they might exist simultaneously with other mutations involved in the MAPK signaling pathway, e.g., *RAS* (see below) \[[@CR95]\]. Disruption of DNA repair can be a prognostic marker for aggressive PTC development, according to TCGA (See Table [2](#Tab2){ref-type="table"}) \[[@CR33]\]. Genotyping of a Polish population showed that 15.6% of samples (*n* = 468) had one of four cell cycle checkpoint kinase 2 (*CHEK2*) mutations known to contribute to carcinogenesis (truncating mutations IVS2 + 1G \> A, 1100delC or del5395 and a mis-sense mutation I157T) \[[@CR11]\]. Wójcicka et al.*,* identified the rs17879961 variant as a risk allele for PTC in a group of 1781 patients (OR = 2.2, *P* = 2.37·10^− 10^) \[[@CR96]\]. In a Greater Poland female population (case/control: 602/829), the c.470C (I157T) homozygous variant was shown to increase the risk of developing PTC by nearly 13-fold (OR = 12.81, *P* = 1.9·10^− 2^) and was observed in 3 women (0.57%), as determined by pyrosequencing \[[@CR97]\]. A heterozygous variant of the same mutation increases the risk by 2-fold (OR = 1.7, *P* = 1.7·10^− 2^).This association was not observed for male patients.

Alterations in cell signaling pathways {#Sec13}
--------------------------------------

### RAS {#Sec14}

Mutations in the family of RAS proteins are associated with AKT phosphorylation and result in preferential activation of the PI3K/AKT pathway in TC by evasion of apoptosis, proliferation and cellular growth \[[@CR98], [@CR99]\]. The RAS family consists of 4 proto-oncogenes: *H-RAS*, *N-RAS*, *K-RAS4A* and *K-RAS4B* \[[@CR100]\]. Although *RAS* mutations are more prevalent in FTC, they are also observed in a subset of PTCs \[[@CR101]\]. Zou et al.*,* detected *KRAS* mutations (p.Q61R and p.S65 N) in 2 samples (2%, 2/88) and an *NRAS* (p.Q61R) mutation in 3 cases (PTC 1%, TCV 2%). Rossi et al.*,* observed 3.4% of samples harboring a somatic *RAS* mutation (*n* = 940), which correlated with an aggressive histotype and poorer prognosis \[[@CR37]\]. Until now, *RAS* mutations have not been found in juvenile thyroid tumors \[[@CR67]\].

### MUC1 {#Sec15}

Mucin (*MUC1*) plays a role in the signaling pathways of proliferation and differentiation of epithelial cells and is crucial in metastasis and tumorigenesis of epithelial cancers such as adenocarcinomas and ovarian cancer \[[@CR102]\]. In PTC, *MUC1* is thought to be a marker of poorer outcome (See Table [2](#Tab2){ref-type="table"}), although this stance is controversial. Using pyrosequencing, Renaud et al.*,* showed that 40% of 94 PTC samples overexpressed *MUC1* in the cytoplasm, which correlated with the presence of the *BRAF*^*V600E*^ mutation in 95% of samples.

Deregulation of protease expression {#Sec16}
-----------------------------------

### TMPRSS4 {#Sec17}

Transmembrane protease serine 4 (TMPRSS4) is a type II transmembrane serine protease overexpressed in several cancer types, including gastric \[[@CR103]\], breast \[[@CR104]\], lung \[[@CR105]\] and thyroid cancers \[[@CR105]--[@CR107]\]. TMPRSS4 promotes cell proliferation, invasion, metastasis and epithelial-mesenchymal transition (EMT) and is predominantly overexpressed in PTC. Kebebew et al.*,* tested 131 tumors by cDNA microarrays, and *TMPRSS4* was one of the 6 genes deregulated in malignant tumors \[[@CR107]\]. Jarząb et al.*,* tested 50 samples from 33 patients (23 PTC, 10 other thyroid malignancies) paired with normal tissue using microarray analysis \[[@CR106]\]. *TMPRSS4* was classified as one of the genes forming a set of markers that distinguish between benign and malignant tumors.

Mutations in transcription regulators {#Sec18}
-------------------------------------

### EIF1AX {#Sec19}

Eukaryotic translation initiation factor 1A/X-linked (EIF1AX) is a major player in the transfer of Met-tRNAf and has a high mutation rate in PTC (1.5%, 6/402). *EIF1AX* is suggested as a potential driver of tumorigenesis in other cancers, e.g., uveal melanoma \[[@CR33], [@CR108], [@CR109]\], and in TC, it is a promising biomarker candidate. This observation is supported by Karanamurthy et al.*,* who detected *EIF1AX* mutation in 2.3% (*n* = 3/86) of tested PTC samples and 1 of 5 PTC FNA samples using NGS \[[@CR110]\]. Almost all of the *EIF1AX* mutations were located at a hotspot A113_splice site at intron 5/exon 6.

### FOXE1 {#Sec20}

The thyroid transcription factor forkhead box E1 (FOXE1) possesses a well-conserved DNA binding domain (FDH) and is crucial in the development of a healthy thyroid \[[@CR111]\]. Deregulation of transcription factors from the FOX family is recognized as an important element of TC progression.

Penna-Martinez et al., used PCR to genotype 196 PTC samples (German population) for the presence of two known susceptibility SNPs in *FOXE1* \[[@CR17], [@CR112]\]. The rs965513 phenotypes "AA" and "AG" were more common in DTC patients in contrast to the "GG" phenotype, which was common in healthy controls. The rs965513 variant is more pronounced in PTC than in FTC \[[@CR112]\]. Mond et al.*,* sequenced 120 PTC tumors for SNPs in the coding region of *FOXE1*. Four mis-sense mutations were found in the FHD (c.821C \> A, p.P54Q; c.943A \> C p.K95Q; c.994C \> T, p.L112F), each in a single tumor. Molecular modeling of the described mutations showed their location in a region highly conserved across species, thus explaining the potential carcinogenic effect \[[@CR111]\].

*TERT* promoter {#Sec21}
---------------

Telomerase reverse transcriptase (TERT) is a catalytic subunit of telomerase vital for the gain of immortality by cancer cells \[[@CR113], [@CR114]\]. Two mutations located in the *TERT* promoter region are associated with carcinogenesis, namely, C-to-T substitution (C1,295,228 T) and C-to-A substitution (C1,295,250A) \[[@CR115]\]. *TERT* promoter mutations appear to be rare in PTC (4.4%, *n* = 455, Chinese population) \[[@CR64]\], but they correlate positively with aggressiveness of the tumor and patient age (See Table [2](#Tab2){ref-type="table"}). These results confirm studies performed by Liu et al.*,* \[[@CR116], [@CR117]\]. *TERT* mutations are less common in PTC (11.3%, *n* = 408) than in ATC (42.6%, *n* = 54) when pooled data are considered \[[@CR118]\]. Studies also show that *TERT* promoter mutations correlate with poorer outcomes and an increase in aggressiveness of the tumor, even if they do not coincide with *BRAF* mutation \[[@CR115], [@CR119]\]. *TERT* promoter mutations are most common in TCV.

Regulatory RNAs {#Sec22}
---------------

RNA-mediated regulatory pathways disrupted in carcinogenesis involve micro-RNA (miRNA, miR) signaling. Micro-RNAs are short, 21--23 nt, non-coding endogenous RNA fragments that regulate expression at the posttranscriptional level \[[@CR120]\]. MicroRNA-deregulated thyroid cancers are collected in Table [3](#Tab3){ref-type="table"}. T Yoruker et al.*,* used RT-PCR to test serum from pre- and post-operative PTC patients to measure the level of micro-RNA expression \[[@CR121]\]. The PTC patient sera levels of 4 miRNAs (miR-222, miR-31, miR-151-5p, let-7) were significantly higher compared with healthy controls, and the miR-21 level was lower (see Table [2](#Tab2){ref-type="table"}). General levels of all miRNAs were lower in the post-operative samples and showed no significant difference with the healthy control group. A similar study was performed by Lee et al.*,* to measure the expression of miR-222 and miR-146b in plasma and tumor tissues \[[@CR122]\]. In recurrent tumors, miRNAs were significantly up-regulated compared with non-recurrent patients and healthy controls. Plasma miRNAs levels decreased after thyroidectomy in both cases. The results, especially miR-222 overexpression, confirm the results of other groups \[[@CR123], [@CR124]\], suggesting that both miRNAs might be used as biomarkers of cancer progression. MiR-221, miR-22, and miR-21 are involved in *PTEN* regulation \[[@CR125]\], whereas miR-126 is associated with angiogenesis \[[@CR120]\], and its expression in PTCs as well as undifferentiated thyroid cancers showed a correlation between miR-126 down-regulation and overexpression of VEGF-A mRNA and protein in tumors. miR-639 expression was upregulated in cancer tissues \[[@CR126]\]. In contrast, expression of miR-20b a regulator of the MAPK/ERK signaling pathway with potential tumor suppressor qualities, was down-regulated in TC \[[@CR127]\]. Samsonov et al.*,* showed the potential differentiating miRNAs (miR-21 and miR-181a) that might be useful in distinguishing PTC from FTC \[[@CR128]\]. Studies conducted by Hu et al.*,* associated down-regulation of miR-940, miR-15a, and miR-16 with PTC phenotype \[[@CR129]\].Table 3microRNAs differentially expressed in PTC and their tissue of originUp-regulationLocalizationSample originDown-regulationLocalizationSample originlet-719q13.41serummiR-15a13q14.2tumor tissuemiR-319p21.3miR-1613q14.2, 3q25.33miR-151-5p8q24.3miR-2117q23.1serummiR-146b10q24.32plasma, tumor tissuemiR-1269q34.3tumor tissuemiR-221Xp11.3miR-94016p13.3miR-222Xp11.3miR-63919p13.12tumor tissue

Follicular thyroid carcinoma (FTC) {#Sec23}
----------------------------------

Follicular thyroid carcinoma is the second most common thyroid malignancy, is considered more aggressive than PTC, and has a 95% 5-year survival rate. Mortality rate and disease aggressiveness increase with the age of the patient at diagnosis \[[@CR130]\].

Hou et al.*,* showed the occurrence of *PTEN* (7%, 6/86 samples) and *PIK3CA* (6%, 5/85 samples) mutations in FTC \[[@CR42]\]. *PIK3CA* gene copy gain was found in 20% of tested samples (24/85). These mutations might affect the activation and regulation of the PI3K/Akt pathway. In contrast to PTC, the *BRAF*^*V600E*^ mutation is generally rare in FTC \[[@CR115]\]. *TERT* promoter mutations (see Table [4](#Tab4){ref-type="table"}) were also tested, but the FTC sample number was low (20 minimally invasive FTCs without metastasis and 3 FTCs with metastasis). Nevertheless, the results correlated positively with the presence of distant metastases (1/2 minimally invasive samples with distant metastases).Table 4Somatic mutations found in FTCs. SNV: Single nucleotide variantGeneLocalizationGene functionMutationDefect in cancerClinial correlationLiteratureGene*ARNT*1q21.3N/ACNVunknownN/AŚwierniak et al.*,* 2016*CHEK2*22q12.1protein kinaseSNV, (C29,108,001A)gain of immortalityN/AŚwierniak et al.*,* 2016, Wójcicka et al.*,* 2014*COL1A1*17q21.33pro-alpha1 chain of type I collagenindel, chr17: 48275120unknownN/AŚwierniak et al.*,* 2016*COX6/DERL2COX6/A1:* 12q24.31, *COX6/A2:* 16p11.2, *DERL2*: 17p13.2N/AtranslocationunknownN/AŚwierniak et al.*,* 2016*FBXW7*4q31.3subunit of ubiquitin protein ligase complex called SCFsCNVunknownN/AŚwierniak et al.*,* 2016*FOXO4*Xq13.1suppressor of transcriptionSNV, (C70,321,204 T)Deregulation of transcription, alters protein structureN/AŚwierniak et al.*,* 2016*IDH1*2q34catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarateLOHunknownN/AŚwierniak et al.*,* 2016*JAK3*19p13.11Protein kinaseintronic regionunknownN/AŚwierniak et al.*,* 2016*KAZN-C1ORF196KAZN*: 1p36.21, *C1ORF196*: 1p36.21unknownGene fusionunknownN/ASalajegheh et al.*,* 2016*KTN1*14q22.3membrane protein involved in organelle motilitydeletion in chr14:56139994unknownN/AŚwierniak et al.*,* 2016*MITF*3p13transcription regulatorinsertion, chr3:69987750unknownN/AŚwierniak et al.*,* 2016*NCOA2*8q13.3epigenetic modifierchr8 position 71,053,835 A \> CunknownN/AŚwierniak et al.*,* 2016*PAX8/PPARGPAX8: 2q14.1, PPARG: 3p25.2*N/At(2;3)(q13;p25) translocationcompetitor inhibitor of PPARγ/ transcription factor similar to endogenous PPARγN/ALacroix et al.*, 2*005, Giordano et al.*,* 2006*PIK3CA3q26.32*catalytic subunit of phosphatidylinositol 3-kinaseCNV (gain)unknownN/AHou et al.*,* 2007*TMPRSS4*11q23.3serine proteaseoverexpressionPromotes cancer cells proliferation, invasion and metastasispositive correlation with staging of tumor nodes metastasisGuan et al.*,2*015*TERT* promoter5p15.33telomerase reverse transcriptaseC228T (rs35809415), C250A, C250T(rs1020948523)unknownpresence of metastasesBae et al.*,* 2016*USP6*17p13.2ubiquitin Specific PeptidaseCNVunknownN/AŚwierniak et al.*,* 2016*WRN*8p12repair od double stranded breaksLOHunknownN/AŚwierniak et al.*,* 2016Regulation of expressionmiR-199a-5p19p13.2regulator of *CTFG* in healthy cellsMicro RNADisruption of regulatory pathways, propagation of cancerDownregulation during tumorigenesisSun et al.*,* 2016

Świerniak et al.*,* performed targeted NGS sequencing of 48 FTC tumors \[[@CR12]\]. The authors identified previously undescribed somatic mutations in both intronic and exonic regions. FTC mutations were found in *FOXO4* (transcription suppressor), *CHEK2* and *NCOA2* (epigenetic modifier) genes. Additionally, 10/18 identified single nucleotide variants (SNVs) were located in the non-coding regions of the studied genes. Other types of mutations included indels in *MITF* and *KTN1* genes (transcription factor and transmembrane kinesin receptor, respectively) and loss of heterozygosity (LOH) in the *IDH1* gene that belongs to the dehydrogenase family. Copy number variations (CNV) in *ARNT* (facilitates transport to the nucleus, transcriptional co-regulator of *HIF1* expression), *FBXW7* (component of the ubiquitin degradation signaling chain) and *USP6* (ubiquitin specific peptidase) were also found in samples with populations of cells highly represented in tumors. In the low-confidence FTC group, a distinct subset of mutations was found, meaning that the differentiation of the two subsets based on their molecular profiles might be possible. In lower-confidence FTC, subset mutations were found in the *COL1A1* gene, which is a fibrin-forming type of collagen. LOHs were identified in *WRN* (belonging to a family of DNA and RNA helicases) and *PPARγ* (member of a nuclear receptor subfamily), among others. A new translocation of unknown function was described, namely, *COX6C/DERL2*. *KAZN/C1ORF196* gene fusion was confirmed in the case study and in 55% (out of 11) of FTC additional samples \[[@CR94]\].

One of the most common genetic events in follicular thyroid cancer is the gene fusion of *PAX8/PPARγ* or PPFP oncoprotein gene \[[@CR131], [@CR132]\]. PAX8 on its own is necessary for the normal development of the thyroid \[[@CR133]\], and PPARγ is a nuclear receptor \[[@CR134]\]. PAX8/PPARγ fusion is present in 35% of FTC tumors on average, can be overexpressed by up to 50-fold compared with endogenous *PPARγ* in tumor tissues \[[@CR135], [@CR136]\] and is probably the effector component of the oncogenic rearrangement \[[@CR137]\].

In FTC, as in PTC, overexpression of *TMPRSS4* is observed in 53.6% (15/28) of the samples, as shown by Guan et al. \[[@CR138]\].

Sun et al.*,* found a positive correlation between FTC tumorigenesis and low levels of miR-199a-5p expression \[[@CR131]\]. MiR-199a-5p was identified as a regulator of the connective tissue growth factor (*CTFG*), which acts as an inhibitor of the cell cycle in healthy tissue. In tumor conditions, both fusion proteins appear to possess binding domains that retain their function in the correct cellular context \[[@CR132]\].

Anaplastic thyroid carcinoma (ATC) {#Sec24}
----------------------------------

Anaplastic thyroid carcinoma is the most aggressive type of TC and contributes to 1--2% of all thyroid cancers and 39% of reported deaths \[[@CR133]\]. The 6- to 12-month mortality rates reach 80%. The high aggressiveness of ATC is caused by dedifferentiation of well-differentiated thyroid cancer forms such as PTC \[[@CR134]--[@CR136]\]. Compared with PTC and poorly differentiated thyroid cancers, the mutation burden in ATC is much larger \[[@CR137]\] (see Table [5](#Tab5){ref-type="table"}).Table 5Somatic mutations found in ATCsGeneLocalizationGene functionMutationDefect in cancerPhysiological effectLiteratureChromosomal Abberation*KAZN*-*CIORF196*1p36.21, 1p36.21N/AGene fusionpotential role in progression and development of tumorsLe Pennec et al.*,* 2015Gene*ARID1A, ARID1B, ARD2, ARID5B, SMARCB1, PBRM1, ATRX*1p36.11, 6q25.3, N/A, N/A, 22q11.23, 3p21.1, Xq21.1components of the SWI/SNF complex, responsible for the chromatin remodelingN/Amutation in one of the complex components leads to dysfunction of the whole complexN/ALanda et al.*,* 2016, Latteyer et al.*,* 2016*ALK*2p23.1anaplastic lymphoma kinaseD1203Hhallmark of anaplastic tumorsN/ABonhomme et al.*,* 2017, Latteyer et al.*,* 2016*ATM*11q22.3cell-cycle checkpoint, response to DNA damageE2039Khigher mutation burden, consistent with the lack of checkpoint functionN/ALanda et al.*,*2016, Kunstman et al.*,*2015*BRAF rs113488022*7q34serine/threonine kinase, response to cell growth factorsV600Econstitutive activation of MAPK pathwayN/ASantarpia et al.*,* 2008, Guerra et al.*,* 2013, Kasaian et al.*,* 2015, Landa et al.*,* 2016, Latteyer et al.*,* 2016*DAXX*6p21.32transcription repressor binding the sumoylated transcription factorsS641Xpotential driver mutationcorrelates with non-thyroidal malignanciesKunstman et al.*,* 2015*EIF1AX*Xp22.12translation initiation factor, transfer of met-trnafSplice site 1 bp upstream of ex6 (C \> G), G9R (C \> G), P2R(G \> C)potential driver mutationN/AKunstman et al.*,* 2015, Landa et al.*,* 2016*ERBB2*17q12downstream enhancer of kinase-mediated signaling pathwaysD387Npotential driver mutationN/AKunstman et al.*,* 2015D873N, A763TN/ABonhomme et al.*,* 2017*HECTD1 rs769574276*14q12ubiquitin protein ligaseL547 Vimpairment of ubiquitynylated proteins degradationN/AKunstman et al.*,* 2015*KMT2A, KMT2C, KMT2D (MLL2), SETD2*11q23.3, 7q36.1, 12q13.12, 3p21.31histone methyltransferases, epigenetic modifiersN/A, KMT2D: Q1892Q (rs753626919), R5389Wimpairment of epigenetic mechanisms, potential driver mutationN/A, KMT2D: correlates with non-thyroidal malignanciesLanda et al.*,* 2016, Kunstman et al.*,* 2015*MET*7q31.2tyrosine-protein kinase metI166Tproto-oncogeneN/ABonhomme et al.*,* 2017*mTOR*1p36.22response element = to stress, possessing kinase activityR164Q (rs573705289), M2327Ipotential driver mutationcorrelates with non-thyroidal malignanciesKunstman et al.*,* 2015*NF1*17q11.2neurofibromatosis related geneP2696L (rs778799019), R2496X (rs752162999)potential driver mutationcorrelates with non-thyroidal malignanciesKunstman et al.*,* 2015, Landa et al.*,* 2016, Latteyer et al.*,* 2016*NOTCH1--4* (*NOTCH2* in Kunstman)1p12transmembrane receptorsNOTCH2: S361F (rs587735797), R1393Hpotential driver mutationcorrelates with non-thyroidal malignanciesKunstman et al.*,* 2015, Landa et al.*,* 2016*PIK3CA*3q26.32PI3K/AKT/mTOR pathway effectorE542K (rs121913273), E545K (rs104886003)mutation of helical domainN/ALanda et al.*,* 2016, Kunstman et al.*,* 2015, Hou et al.*,* 2007*PTEN*10q23.31PI3K/AKT/mTOR pathway effectorN/Atruncated proteinN/ALanda et al.*,* 2016, Hou et al.*,* 2007*RAS*11p15.5, 1p13.2, 12p12.1signal transductionN/Apreferential activation of PI3K-AKT pathwayN/ASantarpia et al.*,* 2008, Guerra et al.*,* 2013, Landa et al.*,* 2016, Latteyer et al.*,* 2016, Hou et al.*,* 2007*TERT* promoter5p15.33telomerase reverse transcriptaseC228T (rs35809415), C250T (rs1020948523)gain of immortalityshorter survivalBae et al.*,* 2016, Landa et al.*,* 2016*TMPRSS4*11q23.3serine proteaseN/Apromotes proliferationpositive correlation with tumor gradeGuan et al.*,* 2015*TP53*17p13.1tumor suppressor proteinY163C (rs148924904)gain of immortalityN/AKasaian et al.*,* 2015, Landa et al.*,* 2016, Bonhomme et al.*,* 2017*USH2A*1q41uscherin, extracellular matrix binding protein interacting with collagen and fibronectinI2189V (rs542406401), D798V (rs148431156), E571K(C \> T), L1727F(G \> A)missense mutationsN/AKunstman et al.*,* 2015*CREBBP*16p13.3histone acetyltransferaseN/Aepigenetic modifierN/ALanda et al.*,* 2016*EP300, BCOR, BCL6*22q13.2, Xp11.4, 3q27.3epigenetic modifiersN/Aabnormal protein modificationsN/ALanda et al.*,* 2016*CTNNB1*3p22.1cytoskeletal anchor, adhesive junctionsQ108HunknownN/AKunstman et al.*,* 2015, Landa et al.*,* 2016*MSH2*2p21DNA mismatch repairN/Again of mutation phenotypeN/ALanda et al.*,* 2016, Kunstman et al.*,* 2015*MSH5*6p21.33A199V (C \> T)N/A*MSH6*2p16.3D736H (G \> C)N/A*MLH1*3p22.2I19M (C \> G), I68M (rs780141938), Q60X (C \> T)N/A*MLH3*14q24.3L264 V (G \> C)N/A

ATC can arise independently, but it often coincides with well-differentiated tumors. Co-occurrence of *BRAF* and *RAS* mutations in ATC suggests its common genetic origin with DTC \[[@CR135], [@CR139], [@CR140]\]. Hou et al.*,* tested 50 ATC tumors and found a high prevalence of mutations associated with PI3K/Akt pathway activation: *PTEN* 16% (8/50) and *PIK3CA* 12% (6/50) \[[@CR42]\]. *RAS* mutations were also identified in 8% (4/50) of samples. The molecular heterogeneity of ATC makes it incredibly difficult to analyze. Kasaian et al.*,* performed whole-genome sequencing of 1 ATC sample and identified 24 somatic mutations, including two heterozygous mutations in *BRAF* (V600E) and *TP53* (Y163C) genes. \[[@CR141]\]. Kunstman et al.*,* tested 22 tumor samples with whole-exome sequencing \[[@CR142]\]. The majority (68%) of the observed variants code for mis-sense mutations. A total of 16 genes were identified as potential drivers of tumorigenesis, 6 of which were present in multiple samples, namely, *NF1* (negative regulator of RAS pathway), *mTOR* (kinase, mediates response to stress), *ERBB2* (EGF receptor), *DAXX* (apoptosis regulator and transcription repressor among other functions), *MLL2* (histone methyltransferase), and *NOTCH2* (regulator of cell fate). In addition, recurrent mutations of *EIF1AX* and *HECTD1* (ubiquitin-transferase activity) and non-synonymous *USH2A* (development of retina and inner ear) mutations were observed. Several of the tested cases presented a hypermutation phenotype, resulting in a high mutation burden of mismatch repair genes. Bonhomme et al.*,* sequenced 94 ATC tumors targeted to *TERT* using NGS and 98 samples using Sanger sequencing \[[@CR143]\]. More than 50% of samples possessed the *TP53* mutations, and *ALK* rearrangements were rare. In total, 210 different alterations were found, including those not previously described in the context of TC, such as *MET* (proto-oncogene) and *ERBB2* mutations. In the Korean population, 60% samples (3/5) had a *TERT* promoter mutation, which coincided with BRAF^V600E^ \[[@CR115]\]. In a study by Landa et al.*,* the presence of *BRAF*^*V600E*^ mutation was observed in 45% out of 33 tumors \[[@CR137]\]. In the same study *RAS* mutations (*H-RAS*, *K-RAS,* and *N-RAS*) occurred in 24% of the samples but were mutually exclusive with *BRAF*^*V600E*^.

Other mutations found in ATCs were *NF1* (3 samples), *PIK3CA* (18%), and *PTEN* (15%). *PIK3CA* mutation tends to co-occur with *BRAF* mutations, whereas *NF1* tends to be present simultaneously with *PTEN* mutations. *EIF1AX* mutations were present in 9% of the 33 studied tumors.

For the first time, Landa et al. reported mutations in components of the SWI/SNF complex (chromatin remodeling system), as reported in 36% (*n* = 33) of tumors. Mutations were also found in histone methyltransferase genes (*KMT2A*, *KMT2C*, *KMT2D*, and *SETD2*) in 24% (n = 33) of ATCs. Additional genes involved in epigenetic processes, i.e., *CREBBP, EP300, BCOR,* and *BCL6,* were mutated at low frequencies*.* One sample carried a *CTNNB1* (p.L347P; WNT signaling pathway) mutation, but this finding was not validated by others. Mutations were also observed in members of the MMR DNA repair pathway (*MSH2*, *MSH6*, and *MLH1*) in 12% of samples. Another DNA damage response element, *ATM,* was mutated in 9% of tested ATCs. Landa et al.*,* reported frequent (73%, n = 33) *TERT* promoter and *TP53* mutations. The *TERT* promoter C228T variant was more common than the C250T variant. *TERT* promoter mutations significantly diminished the survival rate from 732 to 147 days.

Gene fusions are also present in ATC. *KAZN/C1ORF196* was identified by Le Pennec et al.*,* in a case study and confirmed in 11% of additional ATC samples \[[@CR94]\]. Guan et al.*,* observed an increase of *TMPRSS4* expression in all ATC samples (*n* = 12) compared with adjacent normal tissue \[[@CR138]\]. Targeted DNA sequencing for *TP53*, *RAS*, *BRAF*, *ALK,* and *NF1* of 30 formalin-fixed paraffin-embedded (FFPE) ATC tumor samples by Latteyer et al.*,* showed that 28/30 tested samples carried at least one of the tested mutations \[[@CR144]\]. *TP53* mutation was most common (18/30), followed by *NF1* (11/30) and *RAS* family mutations (7/30 combined). It is also worth mentioning that nearly a third of the samples showed residual contaminations of either PTC or FTC tissue, proving the anaplastic tumor heterogeneity.

Zhang et al.*,* tested the expression of myocardin family genes (involved in cell growth arrest, inhibition of differentiation, metastasis and tumor invasion) \[[@CR145]\]. *MRTF-A* was overexpressed in metastatic ATC but was not present in either in primary tumor or the adjacent tissue. Following this finding, down-regulation of miR-206 was identified as the factor leading to the *MRTF-A* overexpression.

Conclusions {#Sec25}
===========

Despite the large number of mutations involved in the tumorigenesis of thyroid carcinomas (Fig. [2](#Fig2){ref-type="fig"}), many tumors remain unclassified by FNA biopsy or even genetic testing. Pagan et al.*,* notes that over 50% of samples tested for a large number of reported mutations already observed in TC by RNA-seq do not show a phenotype, leading to the conclusion that the fast-growing database of somatic and driver mutations in thyroid cancers must be expanded with respect to histological subtype \[[@CR146]\].Fig. 2Genetic changes identified in thyroid cancers of follicular origin. Genes common for all three TC subtypes are marked in red

DNA methylation in thyroid cancer has been extensively studied and reviewed but was not discussed in detail in this review. However, it is worth mentioning that the advances in next-generation sequencing and microarray techniques enable in-depth research on the methylation pattern in GC-rich regions and its effect on gene expression. Most studies focus on pre-determined loci \[[@CR147], [@CR148]\], and fewer are available at the whole-genome scale \[[@CR149], [@CR150]\]. Determination of the methylation patterns can be potentially useful for differentiating between TC subtypes with greater precision. The largest study to date that examines whole-genome methylation was performed as a component of the TCGA project (PTC, *n* = 496) \[[@CR33]\]. In a recent study, Bisarro dos Reis et al.*,* proposed a hyper/hypomethylation genetic signature that allows distinction between TC subtypes (Hürtle cell, PTC, FTC, non-neoplastic tissue and benign lesions, ATC) based on the Illumina 45 k platform, with high sensitivity and specificity (63 and 92%, respectively) \[[@CR151]\]. Methylation can also be used as a prognostic marker of disease outcome, as proposed in the same article. Beltrami et al.*,* proposed the PTC hypomethylation signature of 41 PTC-paired samples (88% of hypomethylation) as a prognostic biomarker of PTC development \[[@CR152]\]. This signature coincides with the presence of the *BRAF*^*V600E*^ mutation (68% of the hypomethylation signature).

In the era of advanced molecular analysis, genetic markers have become a useful tool for the evaluation of thyroid tumor growth and progression. Molecular biomarkers can be applied in the classification of thyroid tumor subtypes and the prediction of disease outcome and might also aid development of systemic molecular therapies in cancers that are refractory to standard treatment. The discovery of specific genetic alterations and mechanisms of thyroid carcinoma development is expected to lead to more personalized treatment for patients with advanced and recurrent disease. Despite the presence of the molecular changes described in this review, the roles of molecular biomarkers in the development of different thyroid tumor subtypes still remain unclear.
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